Most homeowners think of mold as a visible, surface-level problem. Scrub it off, and the danger is gone. That assumption is dangerously wrong when it comes to mycotoxins. Mycotoxins are secondary metabolites — low-molecular-weight toxic compounds — produced by certain mold species as a competitive defense mechanism against bacteria and other fungi. Unlike the mold itself, mycotoxins are not alive. They are chemical molecules that can saturate porous building materials, bind to dust particles, and remain biologically active long after the mold colony that made them has been killed or removed.
The word "mycotoxin" comes from the Greek mykes (fungus) and the Latin toxicum (poison). Of the roughly 400+ known mycotoxins, a relatively small subset — perhaps two to three dozen — pose serious risks to human health at concentrations realistic in indoor environments. The most clinically significant include aflatoxins, ochratoxin A, trichothecenes (including the notorious T-2 toxin and deoxynivalenol), zearalenone, and fumonisins.
Molds do not produce mycotoxins constantly. Production is triggered by environmental stress: competing microorganisms, temperature fluctuations, moisture availability, or substrate competition. This is why two identical Aspergillus colonies grown under different conditions can have radically different mycotoxin loads — and why surface testing alone cannot predict toxin burden.
Not every mold growing in a water-damaged home produces mycotoxins. The following species are the primary culprits in residential settings. Identification requires professional air sampling, bulk material sampling, or ERMI testing — visual inspection cannot determine mold species.
| Mold Species | Mycotoxin Produced | Primary Health Target | Common Growth Site | Risk Level |
|---|---|---|---|---|
| Stachybotrys chartarum (black mold) | Trichothecenes (satratoxin G, H) | Respiratory, neurological, immune | Wet drywall, cellulose insulation, ceiling tiles | CRITICAL |
| Aspergillus flavus / parasiticus | Aflatoxin B1, B2, G1, G2 | Liver, carcinogenic potential | Crawl spaces, stored organic material, HVAC | CRITICAL |
| Aspergillus ochraceus / Penicillium verrucosum | Ochratoxin A (OTA) | Kidney, immune system, nervous system | Damp walls, flooring, AC ducts, wood framing | HIGH |
| Fusarium graminearum / sporotrichioides | Trichothecenes (DON, T-2 toxin), Zearalenone | Gastrointestinal, endocrine disruption | Basement floors, crawl spaces, water-damaged wood | HIGH |
| Fusarium moniliforme / verticillioides | Fumonisins (B1, B2) | Liver, lungs, neural tube (developmental) | Crawl space soil, subflooring, concrete slab cracks | MODERATE–HIGH |
| Alternaria alternata | Alternariol, tenuazonic acid | Respiratory, potential cytotoxicity | Window frames, shower grout, HVAC filters | MODERATE |
| Penicillium chrysogenum | Penicillic acid, roquefortine C | Respiratory, immune sensitization | Wallpaper, carpet backing, wood subfloor | MODERATE |
Mycotoxin illness does not follow a simple, predictable pattern. Responses vary enormously based on the specific toxin, exposure route, duration, individual genetics (particularly HLA-DR haplotype), and pre-existing health status. A family of four in the same house may show dramatically different symptom profiles — one member severely ill, others apparently unaffected.
Short-term high-level exposure — rare outside occupational settings but possible during unprotected remediation or in severely water-damaged structures — can cause pulmonary hemorrhage (especially in infants), chemical-like burning in the throat and airways, acute respiratory distress, severe headaches, and in extreme cases (T-2 toxin), skin blistering and hemorrhagic tissue damage.
| Mycotoxin | Primary Source Mold | Target Organ | Main Exposure Route | Indoor Risk Level |
|---|---|---|---|---|
| Aflatoxin B1 | Aspergillus flavus, A. parasiticus | Liver (hepatotoxic, carcinogenic) | Inhalation, ingestion of contaminated dust | CRITICAL — IARC Group 1 |
| Ochratoxin A (OTA) | A. ochraceus, Penicillium verrucosum | Kidney (nephrotoxic), immune | Inhalation, skin contact, ingestion | HIGH — bioaccumulates |
| Trichothecenes (T-2, DON, satratoxin) | Stachybotrys, Fusarium | Respiratory, neurological, bone marrow | Inhalation (most dangerous), skin contact | CRITICAL — volatile, airborne |
| Zearalenone | Fusarium graminearum, F. culmorum | Endocrine / reproductive (estrogenic) | Ingestion, inhalation of spore dust | MODERATE — hormonal disruptor |
| Fumonisin B1 | Fusarium verticillioides, F. proliferatum | Liver, lungs, neural tube | Ingestion, inhalation in crawl spaces | MODERATE — developmental risk |
This is where mycotoxins become a systemic problem rather than a localized one. A single colony of Stachybotrys in a basement wall cavity can contaminate an entire home through multiple pathways:
Forced-air heating and cooling systems are the most efficient mycotoxin distribution mechanism in a building. When mold grows in return air plenums, on evaporator coils, or in ductwork, every HVAC cycle aerosolizes mycotoxin-laden particles and distributes them to every room. HVAC-distributed mycotoxins are measured throughout structures even when visible mold is confined to a single area. Learn about HVAC mold contamination and why duct cleaning alone is insufficient.
Mycotoxins bind tightly to dust particles. House dust in water-damaged buildings serves as a long-term reservoir — mycotoxins in dust have demonstrated biological activity for 5–10+ years under controlled laboratory conditions. Normal cleaning activities (vacuuming without HEPA filtration, sweeping, even walking on carpets) re-aerosolize toxin-laden dust.
Drywall paper, cellulose insulation, OSB subfloor, carpet padding, and wood framing absorb mycotoxins at the molecular level. Standard cleaning cannot remove them. Studies of Stachybotrys-affected drywall have found satratoxin G detectable on the non-mold-visible face of drywall boards — meaning toxins migrate through materials.
Upholstered furniture, mattresses, clothing, books, and paper documents absorb and retain mycotoxins. This is a critical and frequently overlooked contamination pathway. Remediation professionals experienced in mycotoxin cases will assess belongings separately and may recommend discarding high-porosity items that cannot be effectively decontaminated.
Mycotoxin testing is more complex — and more controversial — than standard mold testing. There is no single universally accepted method, and results must be interpreted carefully.
Developed by the EPA, ERMI uses DNA-based analysis (MSQPCR) of settled dust samples to identify and quantify 36 mold species grouped into "water damage indicator" (Group 1) and "common indoor" (Group 2) categories. ERMI provides a single numerical score; scores above 2–5 are generally considered elevated. ERMI does not directly measure mycotoxins — it identifies the species most likely to produce them. Cost: $200–$400 for a professional dust collection and lab analysis. Learn more about professional mold inspection methods.
A subset of the ERMI, HERTSMI-2 focuses on 5 molds strongly associated with human illness: Stachybotrys chartarum, Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, and Wallemia sebi. Scores are weighted by clinical significance. A HERTSMI-2 score above 11 is considered unsafe for occupancy by clinicians treating mold-illness patients. Cost: $150–$300.
Labs such as Mycometrics (EMMA panel) and Great Plains Laboratory (MycoTOX Profile) offer direct mycotoxin quantification from dust samples or surface swabs using immunoassay or mass spectrometry methods. These tests measure actual toxin concentrations rather than inferring from mold species. Cost: $350–$700 depending on the panel. No regulatory threshold standards currently exist for indoor air mycotoxin concentrations, making interpretation dependent on clinical context.
Urine testing for mycotoxins — offered by labs like RealTime Laboratories and Great Plains — measures urinary excretion of specific mycotoxins including ochratoxin A, aflatoxin, and trichothecenes. Proponents argue it directly measures body burden. Critics (including some environmental medicine specialists) point out that mycotoxins in urine may reflect dietary exposure from contaminated food rather than building exposure, and that no validated reference ranges exist for environmentally exposed populations. The test costs $400–$700 and is rarely covered by insurance. It is most useful when correlated with building testing showing the same mycotoxin species.
For a full comparison of mold testing approaches, see our guide to mold testing costs and methods.
Standard mold remediation — containment, HEPA vacuuming, removal of visibly affected materials, antimicrobial treatment — is insufficient for mycotoxin-contaminated structures. The reasons are fundamental to the chemistry of mycotoxins:
Review the full mold remediation process guide and black mold removal guide for related protocols.
This is one of the most active areas of disagreement between functional/integrative medicine practitioners and conventional medicine. The divide is real and practically significant for patients seeking answers.
Practitioners trained in mold illness (often following the Shoemaker Protocol or similar frameworks) routinely order urine mycotoxin panels, Visual Contrast Sensitivity (VCS) tests, TGF-beta-1, C4a complement, and HLA-DR genetic testing to assess individual susceptibility and body burden. The HLA-DR 4-3-53 haplotype, present in roughly 25% of the population, is associated with impaired mycotoxin clearance — those individuals may accumulate toxins that others excrete efficiently. Functional medicine labs that offer direct-to-consumer ordering allow motivated patients to test without a physician referral.
Most conventional physicians and toxicologists point out that no validated clinical reference ranges exist for urine mycotoxin testing in non-occupationally-exposed populations, that dietary sources (aflatoxin in peanuts, ochratoxin in wine and dried fruit) confound results, and that the treatments promoted by some mold illness practitioners lack randomized controlled trial evidence. The CDC and EPA do not endorse urine mycotoxin testing as a clinical diagnostic standard.
For a practical path forward: building testing (ERMI + direct mycotoxin panel) is scientifically sound and actionable regardless of which medical framework you use. If the building is contaminated, remediation is warranted irrespective of urine test results. See our overview of mold health symptoms and when to seek care and indoor air quality testing.
Mycotoxin remediation costs significantly more than standard mold remediation due to more extensive material removal, specialized PPE, elevated testing requirements, and longer project timelines. Expect costs in the following ranges:
| Scenario | Estimated Cost Range | Key Cost Drivers |
|---|---|---|
| Single room (e.g., bedroom with Stachybotrys in one wall) | $3,000 – $6,000 | Drywall removal, HEPA, encapsulant, clearance testing |
| Basement or crawl space (moderate contamination) | $5,000 – $12,000 | Structural drywall + insulation removal, vapor barrier, encapsulation |
| Whole-home HVAC distribution contamination | $8,000 – $20,000 | Duct system replacement or full NADCA cleaning + HEPA, multi-zone testing |
| Severe structural contamination (multi-room, framing affected) | $15,000 – $30,000+ | Extensive demolition, industrial hygienist oversight, multi-phase clearance |
| Personal belongings remediation / replacement | $2,000 – $8,000 | Ozone treatment (non-porous items only), replacement of porous items |
Insurance coverage for mycotoxin remediation is frequently disputed. Most standard homeowner policies cover sudden water damage but exclude gradual moisture intrusion and mold. Document everything — pre-remediation testing reports, contractor scopes of work, post-remediation clearance — for insurance negotiations. Our professional remediation guide covers insurance documentation strategies.